These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10520672)

  • 1. Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.
    Meltzer D; Johannesson M
    Med Decis Making; 1999; 19(4):371-7. PubMed ID: 10520672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
    Russell LB; Gold MR; Siegel JE; Daniels N; Weinstein MC
    JAMA; 1996 Oct; 276(14):1172-7. PubMed ID: 8827972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations of the Second Panel on Cost Effectiveness in Health and Medicine: A Reference, Not a Rule Book.
    Carias C; Chesson HW; Grosse SD; Li R; Meltzer MI; Miller GF; Murphy LB; Nurmagambetov TA; Pike JJ; Whitham HK
    Am J Prev Med; 2018 Apr; 54(4):600-602. PubMed ID: 29338958
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis 2.0.
    Neumann PJ; Sanders GD
    N Engl J Med; 2017 Jan; 376(3):203-205. PubMed ID: 28099837
    [No Abstract]   [Full Text] [Related]  

  • 8. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the societal perspective in cost-effectiveness analysis useful for decision makers?
    Russell LB; Fryback DG; Sonnenberg FA
    Jt Comm J Qual Improv; 1999 Sep; 25(9):447-54. PubMed ID: 10481813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the U.S. panel on cost-effectiveness in health and medicine.
    Phillips KA; Chen JL
    Am J Prev Med; 2002 Feb; 22(2):98-105. PubMed ID: 11818178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion.
    Brouwer WB; Koopmanschap MA; Rutten FF
    Health Econ; 1997; 6(5):511-4. PubMed ID: 9353652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.
    Richardson JR; Olsen JA
    Health Econ; 2006 Mar; 15(3):311-3; discussion 319-22. PubMed ID: 16389655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of patient preferences for comorbidities in cost-effectiveness analyses.
    Harris RA; Nease RF
    J Health Econ; 1997 Feb; 16(1):113-9. PubMed ID: 10167342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accounting for future costs in medical cost-effectiveness analysis.
    Meltzer D
    J Health Econ; 1997 Feb; 16(1):33-64. PubMed ID: 10167344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
    Weinstein MC; Siegel JE; Gold MR; Kamlet MS; Russell LB
    JAMA; 1996 Oct; 276(15):1253-8. PubMed ID: 8849754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.
    Siegel JE; Torrance GW; Russell LB; Luce BR; Weinstein MC; Gold MR
    Pharmacoeconomics; 1997 Feb; 11(2):159-68. PubMed ID: 10172935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theory and methods of economic evaluation of health care.
    Johannesson M
    Dev Health Econ Public Policy; 1996; 4():1-245. PubMed ID: 10158916
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.